

Bio-Gene Technology Limited (ASX: BGT, “Bio-Gene” or “the Company”), an Australian company developing new insecticides derived from nature to achieve high impact worldwide, presents its financial results for the six months ended 31 December 2025 and an overview of operations for the period.

Highlights

During the period the Company achieved several key milestones, including:

- Qcide was approved by the US Organic Materials Review Institute (OMRI) for listing as a Botanical Pesticide under the USDA National Organic Program in the OMRI Products List
- Positive Flavocide efficacy results presented at a leading conference on tick-borne diseases by researchers from Purdue University
- Additional product applications for both Flavocide® and Qcide® have been identified for assessment following interest from potential new commercial partners
- Several opportunities to develop and launch new products containing Qcide active ingredient have been identified, with shorter market entry timelines
- Bio-Gene and its commercial partners continued to invest in the development and assessment of new Flavocide formulations best suited to its target applications
- The 14th harvest of Qcide was completed, with substantial progress assessing the biomass pre-treatment and extraction to optimise yield
- Two development programs funded by grants totalling A\$3.0m were awarded from the US Department of Defense under the Deployed Warfighter Protection (DWFP) Program
- Bio-Gene Management completed a series of meetings with current and potential commercial and research partners in Singapore, India and Japan
- Completed an annual strategic review of the Company’s product pipeline and strategic partnering priorities across the public health, consumer and crop protection sectors
- Completed the second tranche of a Placement, with total gross proceeds from Placement and Share Purchase Plan (SPP) of A\$2.46m before costs

Commentary and full financial results are contained in the attached Appendix 4D.

Approved for release by the Board of Directors of the Company.

-ENDS-

For further information, please contact:

Tim Grogan
Bio-Gene Technology Limited:
E: timg@bio-gene.com.au

Matthew Wright
NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and toxicity. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited in Australia.

APPENDIX 4D

BIO-GENE TECHNOLOGY LIMITED

ABN 32 071 735 950

HALF YEAR REPORT

Current Reporting Period	Half year ended 31 December 2025
Previous Corresponding Period (PCP)	Half year ended 31 December 2024

Results for announcement to the market

A\$'000

Revenues from ordinary activities	Up	516.4%	to	466
Loss from ordinary activities after tax attributable to members	Down	4.4%	to	(1,400)
Net loss for the period attributable to members	Down	4.4%	to	(1,400)

Explanation

Key notes for the period:

- Under- accrued \$169k of R&D Incentive for the 2025 Financial Year received in the current reporting period.
- Research grants of \$278k recognised during the period in relation to the DWFP Program (see Review of Operation for further details)

Dividends (distributions)	Amount per security	Franked amount per security
Interim dividend	NIL	NIL
Previous corresponding period	NIL	NIL
Record date for determining entitlements to the dividend	N/A	
	31 December 2025	31 December 2024
Net tangible asset per security	0.03¢	0.06¢
Control gained over entities having material effect		
N/A		
Loss of control of entities having material effect		
N/A		
Details of aggregate share of profit (loss) of associated and joint venture entities		
N/A		
This report is based on financial accounts which had been reviewed by independent auditors		

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

APPENDIX 4D – HALF YEAR REPORT
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

<u>Contents</u>	<u>Page</u>
Directors' report	5
Auditor's independence declaration	8
Statement of profit or loss and other comprehensive income	9
Statement of financial position	10
Statement of changes in equity	11
Statement of cash flows	12
Notes to the financial statements	13
Directors' declaration	18
Independent auditor's review report to the members	19

This half year financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made by Bio-Gene Technology Limited during the half year reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001* and the Australian Securities Exchange.

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

DIRECTORS' REPORT

The Board of Directors of Bio-Gene Technology Limited ("Bio-Gene" or the "Company") has resolved to submit the following report together with the financial statements of the Company for the half year ended 31 December 2025.

Directors

The names of the Directors of the Company in office at any time during or since the end of the half year are:

Mr. Alex Ding (Non-Executive Chair)
Mr Tim Grogan (Managing Director and CEO)
Mr. Peter May (Executive Director, Research and Development)
Mr. Andrew Guthrie (Non-Executive Director)
Mr Chris Ramsey (Non-Executive Director)

Review of Operations

During the half year ended 31 December 2025, Bio-Gene Technology Limited advanced the development, regulatory-enabling studies and commercial partnering activities for its two novel insecticidal active ingredients, Flavocide® and Qcide®. Over the period, the Company transitioned from foundational development activities into more advanced regulatory, product development and commercialisation initiatives, supported by strengthened partnerships and external validation of its technology.

Flavocide® Development Progress

Progress during the half year focused on undertaking key studies to generate the regulatory-enabling data required to support future submissions for registration, alongside continued formulation development and partner engagement.

Following completion of the Company's capital raising activities in mid-2025, Bio-Gene commenced the first stages of several major toxicology studies designed to form a core component of the dossier the Company plans to lodge with the Australian Pesticides and Veterinary Medicines Authority (APVMA). These studies are being conducted in accordance with OECD study protocols and are intended to underpin a robust data package to support future multi-jurisdictional registration efforts.

Development of various formulations containing either Flavocide or Qcide continued both internally and in collaboration with commercial partners, targeting applications across public health, consumer and crop protection markets. Positive efficacy data generated by researchers at Purdue University demonstrated greater than 90% mortality of the vector for Lyme disease, *Ixodes scapularis* (Deer tick) nymphs within 24 hours using a prototype formulation containing Flavocide, with residual activity observed for up to four weeks under laboratory conditions. These results provide independent validation of Flavocide's acaricidal potential and support further development.

Under the US Department of Defense Deployed Warfighter Protection (DWFP) grant program, Bio-Gene progressed development of a Flavocide-based wearable mosquito protection device. Engineering and formulation work advanced during the period, with initial small-cage entomological testing demonstrating early evidence of mosquito mortality, validating the wearable "emanator" concept at this stage of development.

DIRECTORS' REPORT

Qcide® Development Progress

Development of Qcide continued across field production, extraction optimisation, regulatory positioning and new product opportunity assessment.

In July 2025, the 14th harvest of Qcide feedstock was completed, with further optimisation of biomass pre-treatment and oil extraction processes to improve yield and efficiency. Ongoing work in Far North Queensland during Q2 FY26 focused on improving plantation performance, yield enhancement and biomass processing to strengthen long-term production capability and prepare for expanded production.

During the half year, Qcide received approval from the US Organic Materials Review Institute (**OMRI**) for listing under the USDA National Organic Program as a 100% natural, non-synthetic botanical pesticide. This listing enables use of Qcide in certified organic production systems, subject to regulatory approvals, and supports the Company's positioning in organic agriculture, eco-label consumer products and sustainable pest control markets.

The Company also identified additional potential Qcide product applications that may offer shorter market entry timelines than previously anticipated, creating opportunities for earlier commercialisation and revenue generation.

Under the DWFP Program, Bio-Gene also initiated development of a Qcide-based indoor residual spray targeting bed bugs, houseflies and other crawling pests. Following delays associated with a US Government shutdown, project commencement activities resumed, with laboratory testing of prototype formulations expected to proceed in early 2026.

Pipeline Development and Commercial Engagement

During the half year, Bio-Gene completed its annual strategic review of its pipeline of eight target product opportunities across public health, consumer and crop protection sectors. All eight opportunities remain current priorities. In addition, new potential commercial applications for both Flavocide and Qcide were identified following increased interest from potential partners and expanding internal technical knowledge of the beta-triketone compound class.

The Company broadened its international engagement with current and prospective commercial and research partners, including meetings in Singapore, India and Japan, and participation in major industry conferences to promote its technology and development products. Growing global concern regarding insecticide resistance and increased outbreaks of mosquito-borne diseases in multiple regions further reinforced the strategic relevance of Bio-Gene's novel, nature-derived modes of action.

Fundraising Activities

In November 2025, the Company received \$519,500 from the Australian Taxation Office under the R&D Tax Incentive program in respect of FY25 expenditure on Flavocide and Qcide development.

During the reporting period, the Company completed the second tranche of its placement and Share Purchase Plan, raising gross proceeds of \$965,000 before costs, contributing to total capital raised of \$2.46 million over the May to July 2025 period.

DIRECTORS' REPORT

Financial and Treasury Activities

The financial results of the Company for the six months ended 31 December 2025 are summarised as follows:

- The Company produced a loss from ordinary activities before income tax and after income tax of \$1,400,687 (2024: \$1,464,772). Research and development costs have been expensed in the period in which they were incurred. Before interest income, tax, depreciation and amortisation the net loss for the period was \$1,397,667 (2024: \$1,449,154).
- Revenues generated for the period of \$466,281 (2024: \$75,648), is inclusive of \$169,502 of prior period R&D Tax Incentive and \$278,948 of Research Grants.
- Cash on hand at balance date was \$1,080,979 (30 June 2025: \$1,138,338).

Events Subsequent to 31 December 2025

Subsequent to the reporting period the following occurred:


- Bio-Gene announced the appointment of Mr Drew Speedy as the Company's new Chief Financial Officer and Company secretary, replacing Mr Edmond Tern;
- The Company announced that two important toxicology studies are underway related to Flavocide. These are:
 - an extended one generation reproductive toxicity study in rats, with preliminary data due in September 2026; and
 - an acute neurotoxicity study of Flavesone in rats, with preliminary data due in May 2026.

Other than the events noted above, there are no matters or circumstances that have arisen since the end of the year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under Section 307C of the *Corporations Act 2001* accompanies this report.

Signed in accordance with a resolution of the Board of Directors.



Alex Ding

Chair

23 February 2026

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

AUDITOR'S INDEPENDENCE DECLARATION
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF BIO-GENE TECHNOLOGY LIMITED

I declare that, to the best of my knowledge and belief, during the half-year ended 31 December 2025 there have been:

- (i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the review.

MVAB Assurance

MVAB Assurance
Chartered Accountants

Sam Claringbold

SAM CLARINGBOLD
Director

Signed at Melbourne this 23rd day of February 2026

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

		Half-Year	
		31 December 2025	31 December 2024
	Note	\$	\$
Other income	2	466,281	75,648
Research & Development		(1,092,843)	(540,416)
Commercialisation Expenses		(244,424)	(229,747)
Management and Employment Expenses		(280,895)	(111,183)
Directors Expenses		(93,573)	(116,408)
Professional Services		(29,001)	(95,541)
Intellectual Property		(102,822)	(428,947)
Depreciation & Amortisation	3	(20,851)	(15,618)
Other Expenses		(2,559)	(2,559)
Loss from continuing operations before tax		(1,400,687)	(1,464,772)
Income tax (expense)		-	-
Loss for the half-year from continuing operations after income tax		(1,400,687)	(1,464,772)
Other comprehensive income (loss) for the period, net of tax		-	-
Total comprehensive loss for the half-year attributable to members of the Company		(1,400,687)	(1,464,772)

Earnings (loss) per share:

Basic loss per share	(0.46¢)	(0.73¢)
Diluted loss per share	(0.46¢)	(0.73¢)

The above Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025

	Note	31 December 2025 \$	30 June 2025 \$
Current assets			
Cash and cash equivalents	4	1,080,979	1,138,338
Trade and other receivables		29,283	472,424
Other current assets		205,790	359,644
Total current assets		1,316,052	1,970,406
Non-current assets			
Property, plant and equipment		10,671	13,351
Intangible assets		147,771	166,242
Total non-current assets		158,442	179,593
Total assets		1,474,494	2,149,999
Current liabilities			
Trade and other payables		146,806	310,463
Employee benefits		158,515	148,459
Financial liabilities		-	51,209
Total current liabilities		305,321	510,131
Non-current liabilities			
Employee benefits		2,388	12,852
Total non-current liabilities		2,388	12,852
Total liabilities		307,709	522,983
Net assets		1,166,785	1,627,016
Equity			
Issued capital	5	23,885,322	22,944,866
Reserves	6	525,090	712,090
Accumulated losses	6	(23,243,627)	(22,029,940)
Total equity		1,166,785	1,627,016

The above Statement of Financial Position should be read in conjunction with the accompanying notes.

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

STATEMENT OF CHANGES IN EQUITY
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

	Note	Fully paid ordinary shares \$	Share option reserve \$	Share loan plan reserve \$	Accumulated losses \$	Total \$
At 1 July 2025		22,944,866	-	712,090	(22,029,940)	1,627,016
Loss for the period		-	-	-	(1,400,687)	(1,400,687)
Other comprehensive income		-	-	-	-	-
Total comprehensive income/(loss) for the year		-	-	-	(1,400,687)	(1,400,687)
Transactions with owners in their capacity as owners:						
Issued capital		965,121	-	-	-	965,121
Transaction costs related to shares issued		(24,665)	-	-	-	(24,665)
Re-allocation of value of equity on forfeiture of loans on shares		-	-	(187,000)	187,000	-
At 31 December 2025		23,885,322	-	525,090	(23,243,627)	1,166,785

	Note	Fully paid ordinary shares \$	Share option reserve \$	Share loan plan reserve \$	Accumulated losses \$	Total \$
At 1 July 2024		21,524,527	194,947	712,090	(19,640,420)	2,791,144
Loss for the period		-	-	-	(2,584,468)	(2,584,468)
Other comprehensive income		-	-	-	-	-
Total comprehensive income/(loss) for the year		-	-	-	(2,584,468)	(2,584,468)
Transactions with owners in their capacity as owners:						
Issued capital		1,496,328	-	-	-	1,496,328
Transaction costs related to shares issued		(75,989)	-	-	-	(75,989)
Re-allocation of value of equity on forfeiture of loans on shares		-	(194,947)	-	194,947	-
At 30 June 2025		22,944,866	-	712,090	(22,029,940)	1,627,016

The above Statement of Changes in Equity should be read in conjunction with the accompanying notes.

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

STATEMENT OF CASH FLOWS
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

		Half Year	
		31 December	31 December
		2025	2024
	Note	\$	\$
Operating activities			
Receipts from customers		-	-
Payments to suppliers and employees inclusive of GST		(1,858,722)	(1,443,165)
Interest received		17,832	40,013
Interest paid		-	-
Research grants		374,782	-
R&D tax incentive		519,502	531,628
Net cash used in operating activities		(946,606)	(871,524)
Investing activities			
Payments for property, plant and equipment		-	-
Repayment of security deposit		-	-
Net cash used in investing activities		-	-
Financing activities			
Proceeds from issue of shares		965,121	-
Payment for share issue expenses		(24,665)	-
Repayments of financial (and lease) liabilities		(51,209)	-
Net cash provided by financing activities		889,247	-
Net increase in cash and cash equivalents		(57,359)	(871,524)
Cash and cash equivalent at 1 July		1,138,338	2,209,558
Cash and cash equivalents at 31 December	4	1,080,979	1,338,034

The above Statement of Cash Flows should be read in conjunction with the accompanying notes.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

Note 1: Basis of preparation

The financial report of Bio-Gene Technology Limited for the half year ended 31 December 2025 was authorised for issue in accordance with a resolution of the Directors on 20 February 2026. Bio-Gene Technology Limited is a company incorporated in Australia and limited by shares which are publicly traded on the Australian Securities Exchange.

The principal activity of the Company during the financial year was developing insecticides/pesticides.

The half-year financial report is a general-purpose financial report prepared in accordance with the *Corporations Act 2001* and AASB 134 '*Interim Financial Reporting*'. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 '*Interim Financial Reporting*'. The half-year financial report does not include notes of the type normally included in an annual financial report and should be read in conjunction with the most recent annual financial report, together with any public announcements made by Bio-Gene Technology Limited.

The accounting policies and methods of computation adopted in the preparation of the half year financial report are consistent with those of the previous financial year and corresponding interim reporting period except as noted below.

Going concern

The financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.

During the half year ended 31 December 2025 the Company incurred an operating loss of \$1,400,687 (2024: \$1,464,772) and a negative cash outflow from operating activities of \$946,606 (2024: \$871,524).

The directors believe that there are reasonable grounds to believe the Company will be able to continue as a going concern after considering the following factors:

- The company has prepared budgets and cash flow forecasts for the next 12 months from the date of signing this report which indicate the company will have a positive cash balance during this period. The cash flow forecasts include further capital raising over the next 12 months.
- The directors believe that there are reasonable grounds to expect the company has the capacity to raise capital. The company has a strong track record of accessing capital when it is required.

These conditions indicate a material uncertainty that may cast a significant doubt about the entity's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business and at the amounts stated in the financial report.

The Directors believe that the Company will continue as a going concern and that it is appropriate to adopt the going concern basis in the financial report. However, should the future fundraising be unsuccessful, the entity may not be able to continue as a going concern. No adjustments have been made relating to the recoverability and classification of assets and liabilities that might be necessary should the Company not continue as a going concern.

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950

NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

Note 2: Other income

	Half year	
	31 December 2025	31 December 2024
	\$	\$
Other income		
Interest revenue	17,831	40,013
R&D tax incentive	169,502	35,635
Research grants	278,948	-
	466,281	75,648

Note 3: Expenses

	Half year	
	31 December 2025	31 December 2024
	\$	\$
Employee salary and benefit expenses:		
Salary and employee benefit expenses	517,012	538,966
Superannuation expenses	50,813	56,814
Share based payments	-	-
Depreciation, amortisation and impairment of non-current assets:		
Depreciation – plant and equipment	2,380	2,830
Amortisation and impairment – intellectual property	18,471	15,393
Operating expenses:		
Foreign currency exchange losses	-	-

Note 4: Cash and cash equivalents

	31 December 2025	30 June 2025
	\$	\$
Cash at bank	80,238	79,327
Deposit at call	700,741	559,011
Term deposits	300,000	500,000
	1,080,979	1,138,338

NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

Note 5: Contributed equity

The Company does not have authorised capital nor par value in respect of its issued shares.

Ordinary shares participate in dividends and the proceeds on winding up of the Company in equal proportion to the number of shares held. At shareholder meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

(a) Movements in contributed equity during the period were as follows:

	31 December 2025	
	Number	\$
Opening balance 1 July 2025	266,419,324	22,944,866
Cancellation of LSP Shares	(3,320,000)	-
Shares issued at 2.3 cents pursuant to Share Placement	41,961,784	965,121
Transaction costs arising on issue of shares	-	(24,665)
Closing balance 31 December 2025	305,061,108	23,885,322

	30 June 2025	
	Number	\$
Opening balance 1 July 2024	201,361,570	21,524,527
Shares issued at 2.3 cents pursuant to Share Placement	50,340,392	1,157,829
Shares issued at 2.3 cents pursuant to Share Purchase Plan	14,717,362	338,499
Transaction costs arising on issue of shares	-	(75,989)
Closing balance 30 June 2025	266,419,324	22,944,866

NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

Note 6: Reserves and accumulated losses

	Note	31 December 2025 \$	30 June 2025 \$
Share options reserve	(a)	-	-
Share loan plan reserve	(b)	525,090	712,090
Total reserves		525,090	712,090
(a) Share option reserve			
Opening balance 1 July		-	194,947
Value of options issued		-	-
Cancellation of unlisted options lapsed during the period		-	(194,947)
Closing balance		-	-
(b) Share loan plan reserve			
Opening balance 1 July		712,090	712,090
Value of shares recognised over vesting period ¹		-	-
Re-allocation of value of shares issued under the LSP which became unrestricted or cancelled during the period ²		(187,000)	-
Closing balance		525,090	712,090
(c) Movement in accumulated losses			
Opening balance 1 July		(22,029,940)	(19,640,419)
Re-allocation of value of options lapsed during the period		187,000	194,947
Net loss for the year		(1,400,687)	(2,584,468)
Closing balance		(23,243,627)	(22,029,940)

Note 7: Operating segments

A segment is a component of the Company that engages in business activities to provide products or services within a particular economic environment. The Company operates in one business segment, being the conduct of research and development activities in the agricultural sector. The Board of Directors assess the operating performance of the Company based on management reports that are prepared on this basis.

Note 8: Commitments and contingencies

There are no commitments and contingencies required to be reported.

¹ The equity settled reserves arise on issue of equity under the LSP or the issue of options

² Amounts are transferred out of the reserves and into issued capital when the loans are repaid, shares issued for nominal value vest or the options are exercised. Amounts are transferred to accumulated losses when the shares or options are cancelled.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE HALF YEAR ENDED 31 DECEMBER 2025

Note 9: Events subsequent to reporting date

Subsequent to the reporting period the following occurred:

- Bio-Gene announced the appointment of Mr Drew Speedy as the Company's new Chief Financial Officer and Company secretary, replacing Mr Edmond Tern;
- The Company announced that two important toxicology studies are underway related to Flavocide. These are:
 - an extended one generation reproductive toxicity study in rats, with preliminary data due in September 2026; and
 - an acute neurotoxicity study of Flavesone in rats, with preliminary data due in May 2026.

Other than the events noted above, there are no matters or circumstances that have arisen since the end of the year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

BIO-GENE TECHNOLOGY LIMITED
ABN 32 071 735 950


DIRECTORS' DECLARATION

In the Directors' opinion:

- the attached financial statements and notes thereto comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporate Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes thereto give a true and fair view of the Company's financial position as at 31 December 2025 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5) of the *Corporations Act 2001*.

On behalf of the directors



Alex Ding
Non-Executive Chair

Dated this 23rd day of February 2026

BIO-GENE TECHNOLOGY LTD
ABN 32 071 735 950**REPORT ON THE HALF-YEAR REPORT TO THE MEMBERS OF BIO-GENE TECHNOLOGY LTD****Conclusion**

We have reviewed the half-year financial report of Bio-Gene Technology Ltd, which comprises the statement of financial position as at 31 December 2025, the statement of profit and loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, a summary of significant accounting policies and other explanatory information, and the directors' declaration. Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Bio-Gene Technology does not comply with the Corporations Act 2001 including:

- (a) giving a true and fair view of the Bio-Gene Technology Ltd's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134: Interim Financial Reporting and the Corporations Regulations 2001.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001 which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

Material Uncertainty Related to Going Concern

We draw your attention to Note 1: Basis of Preparation (Going Concern) in the half-year financial report which indicates that during the half year ended 31 December 2025 the Company incurred an operating loss of \$1,400,686 and a negative cash outflow from operating activities of \$946,606.

As stated in Note 1, this event or condition, along with other matters as set forth in Note 1, indicate a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our conclusions is not modified in respect of this matter.

Responsibility of the Directors for the Financial Report

The directors of the Bio-Gene Technology Ltd are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including giving a true and fair view of the Company's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



MVAB ASSURANCE
Chartered Accountants

Signed at Melbourne this 23rd day of February 2026



SAM CLARINGBOLD
Partner